Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11868047 | 0.88 | HDAC1 (0.61) | HDAC1HDAC6LMNAALDH1A1MEN1 | |
| SCHEMBL1388177 | 0.88 | HDAC1 (0.61) | HDAC1HDAC6LMNAALDH1A1MEN1 | |
| SCHEMBL4869573 | 0.88 | HDAC1 (0.61) | HDAC1HDAC6LMNAALDH1A1MEN1 | |
| SCHEMBL5365608 | 0.87 | KMT2A (0.61) | HDAC1HDAC6LMNAALDH1A1MEN1 | |
| SCHEMBL21922025 | 0.86 | HDAC1 (0.59) | HDAC1HDAC6LMNAALDH1A1MEN1 | |
| SCHEMBL29589266 | 0.85 | ALDH1A1 (0.57) | HDAC1HDAC6LMNAALDH1A1MEN1 | |
| SCHEMBL290434 | 0.85 | ALDH1A1 (0.57) | HDAC1HDAC6LMNAALDH1A1MEN1 | |
| SCHEMBL2797592 | 0.85 | LMNA (0.60) | HDAC1HDAC6LMNAALDH1A1MEN1 | |
| SCHEMBL2794824 | 0.85 | LMNA (0.60) | HDAC1HDAC6LMNAALDH1A1MEN1 | |
| SCHEMBL11554379 | 0.85 | HDAC1 (0.57) | HDAC1HDAC6LMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119255993-A | Thiazole derivative compound and use thereof | 奥托泰利克生物公司 | 2025-01-03 | — | — | CN | claimed |
| EP-4039675-B1 | PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS | LILLY CO ELI (US) | 2024-06-12 | — | — | EP | claimed |
| EP-3775171-B1 | METHODS OF TREATING MINIMAL RESIDUAL CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-01-03 | — | — | EP | claimed |
| EP-3388433-B1 | PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMR BIOTECH CO LTD (CN) | 2023-08-30 | — | — | EP | claimed |
| EP-4021893-A1 | PERK INHIBITING COMPOUNDS | Hibercell, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| CN-114585606-A | PERK inhibiting compounds | 希伯塞尔股份有限公司 | 2022-06-03 | — | — | CN | claimed |
| EP-3551627-B1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN LA ROCHE (CH) | 2022-02-16 | — | — | EP | claimed |
| WO-2021231782-A1 | PERK INHIBITORS FOR TREATING VIRAL INFECTIONS | HIBERCELL, INC. (US) | 2021-11-18 | — | — | WO | claimed |
| WO-2021041973-A1 | PERK INHIBITING COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | claimed |
| CN-103930421-A | Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them | SANOFI SA | 2014-07-16 | — | — | CN | claimed |
| EP-1492784-A2 | SUBSTITUTED 2,3-DIPHENYL PYRIDINES | Merck & Co., Inc. (US) | 2005-01-05 | — | — | EP | claimed |
| WO-2003082191-A2 | SUBSTITUTED 2,3-DIPHENYL PYRIDINES | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | claimed |
| EP-4688746-A1 | CRYSTALLINE FORMS OF (R)-2-AMINO-5-(4-(2-(3,5-DIFLUOROPHENYL)-2-HYDROXYACETAMIDO)-2-METHYLPHENYL)-N-ISOPROPYLNICOTINAMIDE AND METHODS FOR USING THE SAME | Hibercell, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12473296-B2 | Perk inhibiting compounds | HIBERCELL, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250270190-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-08-28 | — | — | US | disclosed |
| CN-119255993-A | Thiazole derivative compound and use thereof | 奥托泰利克生物公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-1565442-A1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-08-24 | — | — | EP | disclosed |
| US-20050176964-A1 | Nicotinamide derivatives useful as p38 inhibitors | GLAXOSMITHKLINE LLC | 2005-08-11 | — | — | US | disclosed |
| WO-2004029026-A1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-04-08 | — | — | WO | disclosed |
| CN-1305472-A | Novel 2,5-pyridinedicarboxylic acid derivatives | DONY WHA PARM IND CO LTD (KR) | 2001-07-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270190-A1 | KIT INHIBITORS | KIT, ABL1, APC | HDAC1 1635/4885HDAC6 2726/4885LMNA 3293/4885 |
| US-12473296-B2 | Perk inhibiting compounds | MAPK1, ERN1, MAP3K20 | HDAC1 637/4885HDAC6 718/4885LMNA 1117/4885 |
| US-20050176964-A1 | Nicotinamide derivatives useful as p38 inhibitors | MAPK1, MAPK7, MAPK6 | HDAC1 77/4885HDAC6 194/4885LMNA 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.